Whether accessing semaglutide telehealth or in-person, insist on documented medical history review, baseline labs, and clear follow-up protocols
Acute kidney injury and ileus have been reported in GLP-1 users with severe GI symptoms
The upper arms also frequently change after weight reduction
Common digestive side effects include: Nausea very common (may affect more than 1 in 10 people) Diarrhoea very common (may affect more than 1 in 10 people) Constipation very common (may affect more than 1 in 10 people), which may seem paradoxical but reflects individual variation in gastrointestinal response Vomiting common (may affect up to 1 in 10 people) Abdominal pain or discomfort common, including bloating, fullness, and dyspepsia Decreased appetite very common, whilst therapeutically beneficial for weight management, this can sometimes be uncomfortable These symptoms typically emerge within the first few weeks of treatment and often improve over time as the body adapts to the medication
Clinical evidence from hospital networks shows that COVID-positive patients on GLP-1 therapy who proactively drank electrolyte solutions (beyond plain water) had shorter illness duration and lower ICU admission rates compared to those who minimized fluid intake due to medication-induced nausea
Monitor and Adjust Medications: Talk to your healthcare provider if youre not seeing the desired results
